• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重肢体缺血:当前及新型治疗策略

Critical limb ischemia: Current and novel therapeutic strategies.

作者信息

Hassanshahi Mohammadhossein, Khabbazi Samira, Peymanfar Yaser, Hassanshahi Alireza, Hosseini-Khah Zahra, Su Yu-Wen, Xian Cory J

机构信息

School of Pharmacy and Medical Sciences, University of South Australia Cancer Research Institute, University of South Australia, Adelaide, SA, Australia.

Department of Genetics, Faculty of Basic Sciences, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.

出版信息

J Cell Physiol. 2019 Sep;234(9):14445-14459. doi: 10.1002/jcp.28141. Epub 2019 Jan 13.

DOI:10.1002/jcp.28141
PMID:30637723
Abstract

Critical limb ischemia (CLI) is the advanced stage of peripheral artery disease spectrum and is defined by limb pain or impending limb loss because of compromised blood flow to the affected extremity. Current conventional therapies for CLI include amputation, bypass surgery, endovascular therapy, and pharmacological approaches. Although these conventional therapeutic strategies still remain as the mainstay of treatments for CLI, novel and promising therapeutic approaches such as proangiogenic gene/protein therapies and stem cell-based therapies have emerged to overcome, at least partially, the limitations and disadvantages of current conventional therapeutic approaches. Such novel CLI treatment options may become even more effective when other complementary approaches such as utilizing proper bioscaffolds are used to increase the survival and engraftment of delivered genes and stem cells. Therefore, herein, we address the benefits and disadvantages of current therapeutic strategies for CLI treatment and summarize the novel and promising therapeutic approaches for CLI treatment. Our analyses also suggest that these novel CLI therapeutic strategies show considerable advantages to be used when current conventional methods have failed for CLI treatment.

摘要

严重肢体缺血(CLI)是外周动脉疾病谱的晚期阶段,其定义为由于受影响肢体的血流受损而导致的肢体疼痛或即将出现的肢体丧失。目前用于CLI的传统疗法包括截肢、搭桥手术、血管内治疗和药物治疗方法。尽管这些传统治疗策略仍然是CLI治疗的主要手段,但诸如促血管生成基因/蛋白质疗法和基于干细胞的疗法等新颖且有前景的治疗方法已经出现,以至少部分地克服当前传统治疗方法的局限性和缺点。当使用其他辅助方法(如利用合适的生物支架)来提高递送的基因和干细胞的存活率和植入率时,这种新颖的CLI治疗选择可能会变得更加有效。因此,在本文中,我们阐述了当前CLI治疗策略的优缺点,并总结了CLI治疗的新颖且有前景的治疗方法。我们的分析还表明,当当前传统方法在CLI治疗中失败时,这些新颖的CLI治疗策略显示出相当大的优势可被采用。

相似文献

1
Critical limb ischemia: Current and novel therapeutic strategies.严重肢体缺血:当前及新型治疗策略
J Cell Physiol. 2019 Sep;234(9):14445-14459. doi: 10.1002/jcp.28141. Epub 2019 Jan 13.
2
Therapeutic angiogenesis using zinc oxide nanoflowers for the treatment of hind limb ischemia in a rat model.使用氧化锌纳米花进行治疗性血管生成以治疗大鼠模型中的后肢缺血
Biomed Mater. 2021 Mar 26;16(4). doi: 10.1088/1748-605X/abebd1.
3
Therapeutic strategies for cell-based neovascularization in critical limb ischemia.严重肢体缺血中基于细胞的新生血管形成的治疗策略。
J Transl Med. 2017 Feb 24;15(1):49. doi: 10.1186/s12967-017-1153-4.
4
Endovascular Therapy Versus Bypass Surgery as First-Line Treatment Strategies for Critical Limb Ischemia: Results of the Interim Analysis of the CRITISCH Registry.腔内治疗与旁路手术作为临界肢体缺血的一线治疗策略:CRITISCH 登记研究的中期分析结果。
JACC Cardiovasc Interv. 2016 Dec 26;9(24):2557-2565. doi: 10.1016/j.jcin.2016.09.039.
5
The BEST-CLI trial: a multidisciplinary effort to assess whether surgical or endovascular therapy is better for patients with critical limb ischemia.最佳下肢缺血血管重建术(BEST-CLI)试验:一项多学科协作的研究,旨在评估手术治疗或血管内治疗对严重肢体缺血患者哪种效果更佳。
Semin Vasc Surg. 2014 Mar;27(1):82-4. doi: 10.1053/j.semvascsurg.2015.01.003. Epub 2015 Jan 22.
6
Defining utility and predicting outcome of cadaveric lower extremity bypass grafts in patients with critical limb ischemia.定义严重肢体缺血患者尸体下肢搭桥术的效用并预测其结果。
J Vasc Surg. 2014 Dec;60(6):1554-64. doi: 10.1016/j.jvs.2014.06.009. Epub 2014 Jul 16.
7
Emerging roles of mesenchymal stem cell therapy in patients with critical limb ischemia.间充质干细胞治疗在重症肢体缺血患者中的新作用。
Stem Cell Res Ther. 2022 Sep 6;13(1):462. doi: 10.1186/s13287-022-03148-9.
8
Lower extremity bypass and endovascular intervention for critical limb ischemia fail to meet Society for Vascular Surgery's objective performance goals for limb-related outcomes in a contemporary national cohort.在当代全国队列中,下肢旁路手术和血管内介入治疗严重肢体缺血未能达到血管外科学会关于肢体相关结局的客观绩效目标。
J Vasc Surg. 2018 Nov;68(5):1438-1445. doi: 10.1016/j.jvs.2018.03.413. Epub 2018 Jun 21.
9
Proportion of patients with critical limb ischemia who require an open surgical procedure in a center favoring endovascular treatment.在倾向于血管内治疗的中心,需要接受开放性外科手术的严重肢体缺血患者的比例。
Am Surg. 2011 Mar;77(3):315-21.
10
Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial.严重肢体缺血患者最佳血管内治疗与最佳手术治疗对比试验(BEST-CLI)的设计与原理
J Am Heart Assoc. 2016 Jul 8;5(7):e003219. doi: 10.1161/JAHA.116.003219.

引用本文的文献

1
Dual-Action flavonol carbonized polymer dots spray: Accelerating burn wound recovery through immune responses modulation and EMT induction.双功能黄酮醇碳化聚合物点喷雾剂:通过调节免疫反应和诱导上皮-间质转化促进烧伤创面愈合
Mater Today Bio. 2025 Feb 11;31:101572. doi: 10.1016/j.mtbio.2025.101572. eCollection 2025 Apr.
2
Transplantation of engineered endothelial progenitor cells with H19 overexpression promotes arterial reendothelialization and inhibits neointimal hyperplasia.过表达H19的工程化内皮祖细胞移植可促进动脉再内皮化并抑制内膜增生。
J Tissue Eng. 2025 Feb 18;16:20417314251315959. doi: 10.1177/20417314251315959. eCollection 2025 Jan-Dec.
3
Atorvastatin Treatment Significantly Increased the Concentration of Bone Marrow-Derived Mononuclear Cells and Transcutaneous Oxygen Pressure and Lowered the Pain Scale after Bone Marrow Cells Treatment in Patients with "No-Option" Critical Limb Ischaemia.
阿托伐他汀治疗显著提高了“无选择”严重肢体缺血患者接受骨髓细胞治疗后的骨髓源性单核细胞浓度和经皮氧分压,并降低了疼痛评分。
Biomedicines. 2024 Apr 22;12(4):922. doi: 10.3390/biomedicines12040922.
4
Alginate-Encapsulated Mesenchymal Stromal Cells Improve Hind Limb Ischemia in a Translational Swine Model.藻酸盐包被间充质基质细胞改善猪转化模型后肢缺血。
J Am Heart Assoc. 2024 May 7;13(9):e029880. doi: 10.1161/JAHA.123.029880. Epub 2024 Apr 19.
5
Dapagliflozin promotes angiogenesis in hindlimb ischemia mice by inducing M2 macrophage polarization.达格列净通过诱导M2巨噬细胞极化促进后肢缺血小鼠的血管生成。
Front Pharmacol. 2023 Sep 21;14:1255904. doi: 10.3389/fphar.2023.1255904. eCollection 2023.
6
Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI).人胎盘间充质干细胞治疗严重肢体缺血(CLI)患者的 1 期临床试验安全性评估报告。
Stem Cell Res Ther. 2023 Jul 5;14(1):174. doi: 10.1186/s13287-023-03390-9.
7
Macrophage-Mediated Inflammation in Skin Wound Healing.巨噬细胞介导体皮肤伤口愈合中的炎症反应。
Cells. 2022 Sep 21;11(19):2953. doi: 10.3390/cells11192953.
8
Emerging roles of mesenchymal stem cell therapy in patients with critical limb ischemia.间充质干细胞治疗在重症肢体缺血患者中的新作用。
Stem Cell Res Ther. 2022 Sep 6;13(1):462. doi: 10.1186/s13287-022-03148-9.
9
Molecular basis of the effect of atorvastatin pretreatment on stem cell therapy in chronic ischemic diseases - critical limb ischemia.阿托伐他汀预处理对慢性缺血性疾病——肢体严重缺血性疾病干细胞治疗作用的分子基础
Physiol Res. 2021 Dec 30;70(Suppl4):S527-S533. doi: 10.33549/physiolres.934718.
10
"Elephant-trunk" negative pressure wound therapy for fixing artificial dermis with basic fibroblast growth factor for critical limb ischemia.“象鼻”负压伤口治疗联合碱性成纤维细胞生长因子固定人工真皮用于治疗严重肢体缺血
Regen Ther. 2021 Sep 4;18:316-320. doi: 10.1016/j.reth.2021.08.002. eCollection 2021 Dec.